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Stereotactic radiosurgery combined with immune checkpoint
inhibitors or kinase inhibitors for patients with multiple brain
metastases of malignant melanoma
Susanne Steraa,*, Panagiotis Balermpasa,m,l,d,*, Oliver Blanckm,e,
Robert Wolffm,c, Stefan Wursterm,g, Rene Baumanne,k, Marcella Szücsi,
Britta Loutfi-Kraussa, Maria-Lisa Wilhelmm,i, Volker Seifertc, Dirk Radesj,
Claus Rödela,l,d, Jürgen Dunste, Guido Hildebrandti, Andreas Arnoldh,
Markus Meissnerb,* and Katharina C. Kählerf,*
The aim was to evaluate toxicity and oncological outcome
of combined stereotactic radiosurgery (SRS) and
immunotherapy or targeted therapy in patients with multiple
brain metastases originating from malignant melanoma.
Despite the fact that both SRS and kinase inhibitors or
immune checkpoint inhibitors are considered standard
treatment options for this indication, the optimal
combination and sequence of these modalities remains
largely unknown, especially for patients with a high number
of brain metastases. For this retrospective analysis,
conducted in two large SRS dedicated centers, we identified
patients with brain metastases from malignant melanoma
and simultaneous application of immunotherapy or
targeted therapy within 30 days of SRS. Forty-eight patients
with a total of 250 lesions (median: 3) were treated in 65
single fraction SRS sessions from 2012 to 2018. After a
median follow-up of 8.3 months (range: 1.2–43.6 months),
the 6-month and 1-year overall survival rates were 75.3 and
50.8%, respectively. The local control rate at one year was
89.5%. Immunotherapy and the application of systemic
treatment directly before or concomitant to SRS were both
associated with improved overall survival (P= 0.037 and
0.045, respectively). We observed four grade III toxicities, of
which only two can be clearly attributed to the combined
treatment. Various combinations of SRS and kinase
inhibitors or immune checkpoint inhibitors appear feasible
and provide promising oncological results and safety
profiles for treating few (n= 1–4) and also multiple (n≥ 5)
melanoma brain metastases. Melanoma Res 29:187–195
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Introduction
Malignant melanoma is one of the most common primary
tumors leading to brain dissemination, with 37% of all
patients with melanoma developing brain metastases
during the course of their disease [1]. So-called targeted
therapies like BRAF and MEK-inhibitors (BRAF/
MEKi), targeting the BRAF-MEK signaling pathway
harboring the most common mutation found in melan-
oma, and recently immune checkpoint inhibitors (ICI)
against PD-1 and CTLA-4 for BRAF-wild type tumors or
as second-line treatment have become standard options
for advanced stage disease and are recommended in
clinical guidelines [2,3]. Together with neurosurgical
removal, single-fraction stereotactic radiosurgery (SRS)
and fractionated stereotactic radiotherapy (SRT) are
standard options for 1–4 central nervous system metas-
tases [2], with an emerging role also in the treatment of
multiple lesions (>4), with or without the addition of
whole-brain radiotherapy (WBRT) [4,5]. Although both
SRS/SRT and novel systemic treatments (i.e. targeted
therapies and ICI) have proven their efficacy, there is a
lack of prospective, randomized data regarding their
combination, especially in terms of sequence and toxicity
[6]. Moreover, several retrospective analyses indicated a
possible improvement in tumor control using these
treatments, and also raised concerns regarding toxicity of
the combined application [7–10]. This bi-centric study,
conducted in two large radiosurgery dedicated centers
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with strict treatment quality control, retrospectively
evaluates the oncological results and adverse effects of
several combinations of kinase inhibitors or ICI with SRS
in a relatively large number of patients (n= 48) with one
or multiple newly diagnosed and/or recurrent brain
metastases (total, n= 250).
Patients and methods
Data acquisition
For this retrospective analysis, we queried the pro-
spectively kept internal databases of our treatment quality
harmonized radiosurgery centers and of the according
university departments of radiation oncology and derma-
tological oncology, after institutional review board
approval (ethics committee of the Johann Wolfgang
Goethe-University Frankfurt, number 395/17, and of the
university of Kiel, number B331/17), to identify all
patients with one or multiple brain metastases from
malignant melanoma, treated with SRS and simultaneous
application of immunotherapy or kinase inhibitors within
± 30 days of SRS.
Treatment and follow-up
For all patients, contrast-enhanced T1-weighted MRI of
the brain with 1–1.5-mm slice thickness, reconstructed in
all three dimensions, was used for delineation of the gross
target volume (GTV) and organs at risk. The planning
target volume (PTV) was defined as the GTV without
any further margin according to common practice for
dedicated SRS machines [5]. A stereotactic frame
(Leksell G Frame; Elekta AB, Stockholm, Sweden) was
used for immobilization for patients treated with the
Gamma Knife System (Leksell Gamma Knife 4C). For
patient treated with the CyberKnife (Accuray Inc.,
Sunnyvale, California, USA), thermoplastic masks were
used for patient immobilization, and patient localization
during treatment was done with stereoscopic radiography
image guidance. Additionally, for the CyberKnife, a
1-mm thin slice planning computed tomography with
according MRI image registration was generated.
Treatment planning was performed using MultiPlan
(Accuray Inc.) for the CyberKnife and Leksell Gamma
Plan 8.3.1 (Elekta) for the Gamma Knife System
according to international best practice guidelines [11].
For the CyberKnife, a mean GTV dose optimization [12]
was performed whenever necessary to generate Gamma
Knife like plans with high central tumor doses. SRS was
applied in a single fraction per metastasis.
Patient follow-up consisted of serial MRI scans (same as
for treatment planning) every 8–12 weeks after SRS.
Multiple MRIs over a short period of time (if needed
every 6–8 weeks) were conducted to diagnose local
tumor regrowth. A continuous increase in the size of a
lesion (defined as area of contrast enhancement) and
contrast uptake in at least two sequential MRI series,
nonresponsive to steroids, combined with corresponding
perfusion-weighted data was considered as local pro-
gression. For differentiation between tumor progression
and pseudoprogression, all clinical and radiological data
were used. Radiological data in patients with brain
metastases routinely included unenhanced T2, FLAIR-,
T1-susceptibility-weighted and diffusion-weighted ima-
ges, ADC-maps, contrast-enhanced T1-weighted images,
and perfusion-weighted images, especially CBV-maps. In
selected cases with inconclusive routine imaging, 1H
spectroscopic chemical shift imaging was added. Since
2016, all neurooncology patients treated with immu-
notherapy in our institution are evaluated according
to the iRANO (Immunotherapy Response Assessment
in Neurooncology) criteria for tumor response. The
perfusion-weighted, contrast-enhanced MRI, including
the additional images as described before, was the main
method for differentiation between progression and
pseudoprogression/necrosis.
Statistical analysis
Follow-up intervals were defined from the date of SRS to
the date of the respective event or last contact. Local
progression (as defined above) was counted as an event for
the endpoint time to local control rate (LCR). Progression
of the primary tumor, occurrence of new metastases and
local progression were counted as events for the time to
progression end point (TTP). Finally, death from any
cause was counted as an event for the endpoint overall
survival (OS). The Kaplan–Meier method and log-rank
test were used for univariate analysis for all time-to-event
endpoints. Cox regression and a backwards approach were
implemented for multivariate analyses. Pearson’s χ2-test
was applied to compare categorical data. P values less than
or equal to 0.05 were considered significant. All statistics
were performed using IBM-SPSS version 25 (IBM Corp.,
Armonk, New York, USA).
Results
Patient and tumor characteristics
Between 1/2012 and 5/2018, a total of 48 patients were
treated for 250 brain metastases in 67 SRS treatment
sessions. The initial diagnosis of the primary malignancy
was between 5/1996 and 2/2018 and the diagnosis of the
brain metastases was synchronous in eight (16.7%)
patients and metachronous in 40 (83.3%) patients. The
first diagnosis of the brain metastases was between
5/2012 and 4/2018, resulting in a median time to brain
metastases after initial diagnosis of 31.7 months (range:
0–216.7 months). The time period between diagnosis of
the cerebral metastases and SRS was 1–226 days, with a
median of 27.5 days.
Of all patients, 30 (62.5%) were male and 18 (37.5%)
female. The median age of the patients at the time of
SRS was 63 years (range: 30–85 years). Patients pre-
sented with a Karnofsky Performance Score (KPS) of
60–100% with a median of 90%. Additional extracranial
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tumor manifestations were present in 32 (66.7%) of the
patients, involving one to six (median 2) extracranial sites
at the time of brain SRS. The patient and tumor char-
acteristics are summarized in Table 1.
Radiosurgery characteristics
Dedicated radiosurgery platforms (Gamma Knife and
CyberKnife) were used for all treatments. All lesions were
treated with single-fraction SRS. Owing to whole-brain dose
constraints, the treatment was regionally split in two fractions
separated by four days in two cases (i.e. the metastases in one
regional half brain were treated in a single fraction in one
session and the other metastases also in a single fraction in a
second session). The median total number of radiosurgically
treated brain metastases per patient was 3 (range: 1–30). The
maximum number of treated metastases in one SRS session
was 20, and for a split SRS treatment 21. Of all patients, 34
(71%) patients received only one SRS session, whereas nine
patients had two and five had three sessions owing to distant
intracranial recurrence during follow-up. The median PTV
per lesion was 0.23 cm3 (range: 0.01–12.27 cm3) and the
median cumulative PTV was 1.20 cm3 (range:
0.04–28.78 cm3). The median prescribed PTV dose to
greater than 98% tumor coverage was 18.0Gy (range:
15–20Gy), resulting in a median biological equivalent dose
with α/β=10Gy (BED10) of 50.4Gy10. Prescription was
performed on the median 66% isodose resulting in a
maximum dose in each central metastasis of median 28.3Gy
(BED10=108.6Gy10; range: 20.0–36.7Gy). According to
the International Commission on Radiation Units and
Measurements (ICRU) report 91 [13] and our national
guidelines [14], the PTV D98% and D2% (dose received by
98% and 2% of the PTV, respectively) should be reported,
though the differences for our cohort were small and details
are summarized in Table 2. Twelve (25%) patients also
received WBRT, three of them before and nine of them
after SRS.
Targeted therapy and immunotherapy characteristics
The simultaneously applied systemic therapy was immu-
notherapy in 45 SRS series, kinase inhibitors in 18 cases
and a combination of both in four cases. The kind of
simultaneous therapy depended mainly on the mutation
state of the primary tumor, which was BRAFmutated in 23
(47.9%) patients, neuroblastoma rat sarcoma oncogen
mutated in eight (16.7%) patients and without known
mutation in 17 (35.4%) patients, and secondly on previous
failed therapies. Nivolumab, ipilimumab and pem-
brolizumab were used as immunotherapy, given every 2–3
weeks, and dabrafenib, trametinib, vemurafenib, cobime-
tinib and buparlisib as kinase inhibitors, given daily, in our
combined patient cohort.
If given before SRS, the last application of the systemic
therapy was in median 7.7 days before SRS, and the first
application in median 9.2 days after SRS. In 48 of the 67
SRS sessions (71.7%), patients received their systemic
therapy without interruption, delay or dose reduction; 35
patients of these patient received immunotherapy. For
the two split session cases, immunotherapy was given in
between the 3-day break. In seven (10.8%) cases the
specific systemic therapy was completely stopped before
SRS: for three of them the break was due to change of
the immunotherapy or targeted therapy agent. In 64.2%
of the treatment series, prescription of dexamethasone
for few days after SRS was necessary.
Tumor control and survival
After a median follow-up of 8.3 months (range:
1.2–43.6 months), the 6-month OS was 75.3%, the 1-year
OS was 50.8% and the 2-year OS was 31.8%. The
progression-free interval after SRS was 42.3% at 6 months
and 25.5% at 1 year. The LCR was 89.5% at 1 year
(Fig. 1a–c), and all local failures were re-treated with
radiosurgery [15].
Despite the small number of events, we conducted
exploratory univariate analyses for these three oncologi-
cal end points. For OS and TTP, we included following
factors with possible effect in univariate analyses: sex,
age (> median vs. younger), Karnofsky Performance
State, intracerebral progression, mutation state, kind of
system therapy and extracranial manifestation. For LCR,
we included sex, age, mutation state, kind of system
Table 1 Patient and tumor characteristics
Total (%)
Patients 48
Lesions/patient 250
Median 3
Sex
Male 30 (62.5)
Female 18 (37.5)
Age
Median (range) in years 63.0 (30–85)
Karnofsky index
Median (range) in % 90 (60–100)
Extracranial manifestation
No 16 (33.3)
Yes 32 (66.7)
1 9 (18.8)
2 9 (18.8)
3 3 (6.3)
4 5 (10.4)
5 4 (8.3)
6 2 (4.2)
Mutational status
BRAF 23 (47.9)
NRAS 8 (16.7)
Wild type 17 (35.4)
Appearance of metastasis
Metachronous 40 (83.3)
Synchronous 8 (16.7)
Interval between diagnosis of primary tumor and metastasis
Median (range) in months 31.7 (0.0–216.7)
Interval between diagnosis of primary tumor and SRS
Median (range) in months 33.75 (0.4–217.2)
Interval between diagnosis of metastasis and SRS
Median (range) in days 27.5 (1–226)
BRAFi, BRAF/MEK inhibitor; NRAS, neuroblastoma rat sarcoma oncogen; SRS,
stereotactic radiosurgery.
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therapy, PTV volume and PTV dose with several
equivalents.
Regarding OS, the application of immunotherapy sig-
nificantly correlated with a better outcome (P=0.031,
Fig. 2a). This was also the case for an application of systemic
therapies directly before or concomitant to SRS when com-
pared with cases with initiation of systemic therapy shortly
after SRS (P=0.039, Fig. 2b). These two parameters
remained significant in multivariate analysis (P=0.037 and
0.045, respectively). In the subgroup of patients treated
with ICI, PD-1-inhibitors alone or as combination-partners
were associated with improved survival in univariate ana-
lysis compared with anti-CTLA-4 treatment (P=0.038,
Fig. 3). When examining TTP, the sequence of application
(before/concomitant to vs. after SRS) was the only significant
factor associated with outcome (P=0.027, Fig. 2c), whereas
ICI medication showed only a trend for better results com-
pared with kinase inhibitors (P=0.112). For LCR, we could
not identify any factors with positive or negative effect.
Neither age, sex, Karnofsky performance status, number of
metastases nor extracranial involvement sites proved to have
Table 2 Treatment characteristics
Total (%)
Treatment series
Per patient
1 34 (70.8)
2 9 (18.8)
3 5 (10.4)
Per platform
CyberKnife 60 (89.6)
GammaKnife 7 (10.4)
Number of treated lesions
1 23 (34.8)
2 11 (16.7)
3 5 (7.6)
4 8 (12.1)
5 4 (6.1)
6 5 (7.6)
7 2 (3.0)
9 4 (6.1)
≥10 4 (6.0)
PTV volume cumulative
Median (range) in cm3 1.2 (0.039–28.78)
PTV dose
Median (range) in Gy 18.0 (15.0–20.0)
PTV dose BED10
Median (range) in Gy 50.4 (37.5–60.0)
PTV dose max
Median (range) in Gy 28.3 (20.0–36.7)
PTV dose BED10 max
Median (range) in Gy 108.6 (60.0–171.4)
PTV dose D98%
Median (range) in Gy 18.2 (15.1–20.3)
PTV dose BED10 D98%
Median (range) in Gy 51.2 (38.1–61.3)
PTV dose D2%
Median (range) in Gy 27.8 (19.6–36.0)
PTV dose BED10 D2%
Median (range) in Gy 104.9 (58.0–165.3)
Whole-brain radiotherapy
Total 12 (25.1)
Before SRS 3 (6.3)
After SRS 9 (18.8)
Systemic therapy (SRS series)
Immunotherapy 45 (67.1)
PD-1/PD-L1 22 (32.8)
CTLA-4 14 (20.9)
PD-1/CTLA-4 9 (13.4)
Kinase inhibitor 18 (26.9)
ICI +BRAFi 4 (6.0)
Dexamethasone during SRS
No 24 (35.8)
Yes 43 (64.2)
Median (range) (mg) 4 (0–8)
Timing of SRS and systemic therapy ICI (in %) BRAFi (in %)
Before/concomitant to SRS 40 (61.5) 15 (23.1)
Start after SRS 7 (10.8) 3 (4.6)
BED, biological equivalent dose; BRAFi, BRAF/MEK-inhibitor; ICI, immune
checkpoint inhibitor; PTV, planning target volume; SRS, stereotactic radiosurgery.
Fig. 1
(c)
(b)
(a)
Oncological outcome. BRAFi, BRAF/MEK inhibitor; ICI, immune
checkpoint inhibitor; SRS, stereotactic radiosurgery.
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any effect on tumor control or survival. These results are
presented in Table 3.
Toxicity
Of 48 patients, 34 (70.8%) did not experience any toxicity,
either SRS related or systemic treatment related. Three
patients experienced altogether four grade III toxicities,
attributable to both the SRS and concomitant systemic
therapy, namely, one patient with autoimmune pancrea-
titis, one patient with autoimmune hypophysitis and one
patient with two cases of symptomatic radio-necrosis, with
symptoms that resolved after surgery. The other eleven
patients with adverse effects after SRS showed subclinical
radionecrosis, intracerebral bleeding, headache or other
mild neurological symptoms, which may be attributed to
SRS, such as nausea. Diarrhea, leucopenia, autoimmune
hepatitis, and autoimmune pancreatitis were also observed
and are most likely attributed to the systemic therapy. One
patient experienced a seizure, and the differentiation
between treatment-toxicity and tumor progression was
inconclusive.
Of the four patients with radionecrosis, only one had
WBRT. The patient with the grade III radionecrosis
(operated) had received three series of SRS for a total of
30 metastases with regionally overlapping treatment
fields. An overview of all adverse events and the corre-
sponding systemic treatments can be found in Table 4.
Discussion
Despite the fact that both SRS and targeted/immune-
therapies are considered standard treatment options for
brain metastases of malignant melanoma, the optimal
combination strategy and sequence of these modalities
remains largely unknown [3,4,7,16,17]. The implementa-
tion of BRAF/MEKi and the advent of immunotherapy
revolutionized treatment of metastatic melanoma com-
pared with the unsatisfactory control rates provided with
classical chemotherapy [18]. Combining such agents with
radiotherapy opens new promising options for synergistic
effects but also raises safety and feasibility concerns as new
and unexpected toxicities may arise [19].
In this context, SRS appears to be the ideal irradiation
technique for this indication, as it provides maximal sparing
of healthy tissue, and treatment duration is much shorter as
in the case of fractionated radiotherapy, allowing for only
very short interruptions of systemic treatments where
necessary. Besides, although novel drugs provide not only
Fig. 2
(c)
(b)
(a)
Oncological outcome depending on kind of and timing of systemic
therapies. BRAFi, BRAF/MEK inhibitor; ICI, immune checkpoint
inhibitor; SRS, stereotactic radiosurgery.
Fig. 3
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Oncological outcome depending on immunotherapy agents. PD-1, anti-
programmed cell death protein 1; CTLA-4, anti-cytotoxic T-lymphocyte-
associated protein 4.
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improved systemic but also local control [17], recent efforts
to omit, or at least defer, radiotherapy in patients with brain
metastases, using only upfront targeted therapies, resulted
in significantly inferior survival in patients with non-small
cellular lung cancer [20]. On the contrary, there exist pre-
clinical and clinical data and a strong biological rationale for
combining both BRAF-inhibitors or ICI with radiotherapy:
Samabade et al. [21] could demonstrate that many radio-
resistant melanoma cell lines were BRAF mutated, so that
BRAF inhibition enhanced radiosensitivity. Dasgupta et al.
[22] showed that the simultaneous BRAF inhibition and
irradiation led to more apoptotic tumor cells and prolonged
survival of mouse models. In a clinical study, blood derived
from patients with melanoma treated with vemurafenib also
showed increased sensitivity to radiation [19]. Ionizing
radiation can also facilitate immune response through var-
ious mechanisms like secretion of danger signals (e.g.
HMGB-1 and calreticulin) and increased antigen pre-
sentation, potentially improving response to anti-CTLA-4
and anti-PD-1 treatment [23–25]. However, the necessary
minimum and maximum radiation doses and the fractio-
nation schemes for enabling such effects are still widely
under investigation. Strong evidence, at least for immu-
notherapy, suggests that higher radiosurgery doses are
required [26].
In the present study, we examined and compared the
aforementioned combinations (SRS+BRAF/MEKi and
SRS+ ICI) regarding feasibility/toxicity and oncological
results in a cohort of 48 patients with 250 brain metas-
tases treated with SRS dedicated platforms (Gamma
Knife and CyberKnife with Gamma Knife like planning,
i.e. very inhomogeneous dose distribution inside the
central metastases). Although there exist some recent
data about toxicity and efficacy of similar regimens, all of
these series are retrospective, mostly included smaller
patient numbers, or investigated solely and separately the
combination of SRS with BRAF/MEKi [10,27–29] or
with ICI [30–33]. Furthermore, only a limited number of
metastases were treated with each SRS session in those
studies. We could identify only two larger series includ-
ing SRS combined with all possible approved drugs for
metastatic melanoma: Ahmed et al. [34] reported on
96 patients treated for 314 lesions, but 20 cases
with chemotherapy were also included among them.
Furthermore, the patients were all treated at a linear
accelerator, the median number of irradiated lesions per
patient (with the exception of the chemotherapy cases)
was 2 and the median GTV amounted 0.14 cm3, whereas
in our series, the median number of treated lesions per
patient was higher (n= 3) and the median GTV was
Table 3 Statistical analysis
Overall survival Time to progression Local control
Univariate analysis (P value)
Age (>63 vs. ≤63 years) 0.591 0.313 0.582
ECOG Index (0 vs. 1) 0.547 0.347
Sex (male vs. female) 0.418 0.290 0.882
Intracerebral progression 0.519 0.000
Mutational status (BRAF/NRAS vs. wild) 0.289 0.117 0.749
Mutational status (BRAF vs. NRAS) 0.370 0.939 0.458
Mutational status (BRAF vs. wild type) 0.751 0.219 0.560
Mutational status (NRAS vs. wild type) 0.295 0.662 0.542
Immunotherapy vs. kinase inhibitor 0.031 0.112 0.754
Immunotherapy agents (anti-PD-1 monotherapy and combinations vs. anti-CTLA-4) 0.038 0.169 0.195
Application of systemic therapies (directly before/concomitant vs. after SRS) 0.039 0.027 0.206
Extracranial manifestation (no vs. yes) 0.107 0.684
Extracranial manifestation (1 vs. ≥2) 0.201 0.671
Extracranial manifestation (2 vs. ≥3) 0.065 0.792
Extracranial manifestation (3 vs. ≥4) 0.143 0.792
Number of metastases (3 vs. ≥4) 0.471 0.863
Number of metastases (4 vs. ≥5) 0.471 0.863
Number of metastases (5 vs. ≥6) 0.471 0.863
Number of metastases (10 vs. ≥11) 0.471 0.863
PTV volume (>0.225 vs. ≤0.225 cm3) 0.296
PTV volume all (>1.2 vs. ≤1.2 cm3) 0.894
PTV dose (>18.0 vs. ≤18.0 Gy) 0.408
Maximum PTV dose (>28.3 vs. ≤28.3 Gy) 0.353
PTV D98 (>18.2 vs. ≤18.2 Gy) 0.376
PTV D98 BED10 (>51.2 Gy vs. ≤51.2 Gy) 0.376
PTV D2 (>27.8 Gy vs. ≤27.8 Gy) 0.400
PTV D2 BED10 (>104.9 Gy vs. ≤104.9 Gy) 0.400
WBRT (after SRS vs. no) 0.116 0.745 0.593
Multivariate analysis (P value)
Immunotherapy vs. kinase inhibitor 0.037
Timing of systemic therapies (directly before/concomitant vs. after SRS) 0.045
Immunotherapy agents (anti-PD-1 monotherapy and combinations vs. anti-CTLA-4)a 0.142
BED, biological equivalent dose; CTLA-4, anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD-1, anti-programmed cell death protein 1; NRAS, neuroblastoma rat
sarcoma oncogen; PTV, planning target volume; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy.
aOnly patients with immunotherapy and the variables ‘timing’ and ‘immunotherapy agents’ included for this analysis.
Bold values indicate significance (P<0.05).
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somewhat larger (0.23 cm3). Despite these differences in
treated targets and platform (and correlated dose pre-
scription), the median OS after SRS for all patients was in
both studies between 8 and 9 months, and the 1-year
LCRs, with 89.5% (our data) and 83%, surprisingly
similar. Moreover, in both analyses, there was no factor
with a significant effect on local control, and the only
type of systemic therapy that affected OS was immu-
notherapy, which was generally associated with improved
survival compared with BRAF/MEKi treatments. In an
even larger study, Kotecha et al. [35] analyzed 366
patients with 793 SRS-treated lesions (median number
per patient 2). Only 15% (n= 54) of the patients received
ICI or BRAF/MEKi; the interval between SRS and sys-
temic therapy was very heterogeneous, and no exact
volume calculation was reported. The BRAF status had
not been available for all patients, but BRAF inhibition
within 30 days of SRS was associated with lower local
failure rates. Interestingly, ICI seemed to be associated
with local only in BRAF-mutated cases. The 1-year OS in
the BRAF-positive subgroup reached 53% and LCR for
the entire cohort was 85.0%, which is in line with our data
(51.0 and 89.5%, respectively). In a multivariate analysis,
both BRAF/MEKi and ICI correlated with improved
survival, but only BRAF/MEKi with LCR. There was
no direct comparison between the two different treat-
ment groups, and the heterogeneous inclusion criteria
(e.g. patients after surgery, or with unknown BRAF-
status were included) make interpretation of the data
challenging.
Mounting evidence suggests an enhanced effect of con-
comitant application of SRS together with BRAF/MEKi
[35] and ICI [31–33]. Yet, it remains to be elucidated how
narrow the timeframe of the combination should be and if
drug application shortly before or after SRS could provide
comparable results. In the present study, we could also
show an association between timing and outcome, with a
concomitant setting appearing superior in terms of OS
and TTP. However, as the LCR did differ depending on
the sequence of SRS and targeted treatment, this pro-
longed survival may be attributed to improved systemic
control. It remains unclear, if this improved systemic
control can be associated with SRS, for example, through
immunological and/or abscopal effects, or with cohort-
related bias. Nevertheless, the 1-year OS (50.8%) and
1-year LCR (89.5%) were similar or even better com-
pared with historical series of SRS alone, although the
median and maximum number of metastases in our
cohort was higher (n= 3 and 20, respectively) [36–38].
Intriguingly, clinical parameters with known effect on
outcome, like previous WBRT, number of cerebral or
extracranial metastases and Karnofsky status [39] did not
seem to play a crucial role in this cohort. Notwithstanding
the limitations of this retrospective analysis, a highly
effective local treatment, like SRS, combined with
modern, active systemic therapy may successfully control
even advanced disease stages. Preclinical data seem to
confirm a synergistic effect for immunotherapy and SRS,
which might also explain the higher survival rates
observed in our series [40].
The last exploratory survival analysis conducted was a
comparison of the different immunotherapy regimens in
the respective subgroup treated with ICI. Patients
receiving anti-PD1 treatment had a clear survival benefit
compared with those treated with anti-CTLA-4 mono-
therapy in the univariate analysis, without any significant
difference in local control or progression-free survival.
The improved OS after anti-PD1 treatment (mono-
therapy or combined with anti-CTLA-4) is in accordance
with the large prospective trials for metastasized melan-
oma [41] and such not surprising. Although the similar
Table 4 Toxicity
Adverse effect System therapy
Grade I/II
[n (%)]
Grade III
[n (%)]
% of all treated lesions n=250
Radionecrosis
Ipilimumab 1 (0.4)
Nivolumab/
Ipilimumab
1 (0.4) 1 (0.4)
Pembrolizumab
Vemurafenib 5 (2.0)
Dabrafenib 1 (0.4)
Dabrafenib/
Trametinib
1 (0.4) 1 (0.4)
Intracerebral bleeding
Ipilimumab 1 (0.4)
Pembrolizumab 2 (0.8)
Dabrafenib 1 (0.4)
% of all SRS series n=67
Headache
Nivolumab/
Ipilimumab
1 (1.5)
Pembrolizumab 1 (1.5)
Nausea
Nivolumab/
Ipilimumab
1 (1.5)
Pembrolizumab 1 (1.5)
Leucopenia
Vemurafenib 1 (1.5)
Diarrhea
Nivolumab/
Ipilimumab
1 (1.5)
Seizure
Nivolumab/
Ipilimumab
1 (1.5)
Other neurological
symptoms
Ipilimumab 1 (1.5)
Nivolumab/
Ipilimumab
1 (1.5)
Pembrolizumab 1 (1.5)
Vemurafenib 1 (1.5)
Autoimmune hepatitis
Ipilimumab 1 (1.5)
Pembrolizumab 1 (1.5)
Autoimmune
pancreatitis
Nivolumab/
Ipilimumab
1 (1.5)
Autoimmune
hypophysitis
Pembrolizumab 1 (1.5)
SRS, stereotactic radiosurgery.
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local control for both groups could easily be explained
through the added effect of radiosurgery, the lack of
significance in terms of time to progression or OS in
multivariate analysis is rather associated with the very
limited number of patients and events for these two small
sub-cohorts of the ICI-subgroup.
Regarding toxicity, we could only identify four grade III
adverse events of which only two were related to SRS: two
cases of clinically apparent radio-necrosis associated with a
status epilepticus, requiring surgical, one after combined
treatment with ICI and one with BRAFi, both in the same
patient, but after different SRS sessions. This relatively
low rate is in accordance with the literature reporting grade
III toxicity in general less than 10%, whereas series
examining only CTLA-4 inhibitors reported higher rates
of radionecrosis of about 20% [30,33]. Note that these
more toxic agents were underrepresented in our cohort.
Recent comprehensive reviews on this topic confirm our
observations [6,42]. Moreover, there was no statistically
significant difference in the steroid requirement between
the different patient groups. Some authors associate
simultaneous application of vemurafenib and radiotherapy
with increased toxicity [10,35]. However, WBRT and
(resulting) skin toxicity were also included in these studies
and the overall rates of severe adverse effects remain low.
No unexpected or life-threatening toxicity occurred, and
all ICI-associated or BRAF/MEKi-associated adverse
effects were manageable and resolved.
This study has several limitations: the limited number of
patients and lesions, the heterogeneity of treatment
regimens used, and the retrospective nature of the ana-
lysis even though our databases are prospectively gen-
erated under strict institutional protocols. Furthermore,
the tumor volumes were generally small in our cohort and
we applied only single fraction doses. For larger metas-
tases, a fractionated approach may be necessary [43].
Despite these limitations, this study, reporting of 250
metastases, is one of the largest so far and one of the very
few including patients treated with both kinase inhibitors
and ICI in various combinations.
Taken together, the combination of SRS with novel
targeted agents is a feasible option with an acceptable
safety profile and good clinical outcome even for treating
a higher number of metastases and could be used to
defer WBRT.
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